

The Fluvoxamine XR shortage continues into 2026. Here's the latest on supply, pricing, and what patients can do to keep their treatment on track.
If you take Fluvoxamine XR for OCD or social anxiety, you've likely been affected by one of the longest-running drug shortages in recent years. The shortage of Fluvoxamine extended-release capsules began in early 2024, and as we head deeper into 2026, supply remains inconsistent.
This article gives you the latest update on what's happening with Fluvoxamine XR supply, how much it costs, what new options are available, and how to find it in stock.
Yes. As of early 2026, Fluvoxamine Maleate Extended-Release Capsules remain on the American Society of Health-System Pharmacists (ASHP) drug shortage list. The shortage was first reported in February 2024 and has persisted for nearly two years.
Both manufacturers of generic Fluvoxamine ER — Par Pharmaceuticals and Teva Pharmaceuticals — have experienced intermittent supply issues. While both companies have had some product available at various times, neither has been able to consistently meet demand for the 100 mg and 150 mg capsule strengths.
The original brand, Luvox CR, was discontinued years ago, so there is no brand-name fallback option.
Several factors have combined to create and prolong this shortage:
For a deeper look at the causes, see: Why Is Fluvoxamine XR So Hard to Find?
The cost of Fluvoxamine XR varies significantly depending on whether you have insurance and which pharmacy you use:
By comparison, Fluvoxamine immediate-release tablets cost as little as $16 to $22 for a 30-day supply with a coupon — making the IR formulation a significantly more affordable option.
For more ways to reduce costs, read: How to Save Money on Fluvoxamine XR
While no new manufacturers have entered the market for Fluvoxamine ER capsules specifically, there are several options patients should know about:
The most straightforward alternative is switching to the IR formulation. It contains the same active ingredient and is equally effective. The main difference is that IR tablets are taken twice daily instead of once at bedtime. IR tablets are more widely available and much cheaper — starting around $16 per month with coupons.
If Fluvoxamine IR isn't right for you, other SSRIs like Sertraline (Zoloft), Fluoxetine (Prozac), and Paroxetine (Paxil) are all FDA-approved for OCD and/or anxiety disorders. These are all available as inexpensive generics with no current shortage issues. See our full comparison: Alternatives to Fluvoxamine XR
If you're having trouble getting an appointment with your regular psychiatrist or doctor to discuss alternatives, telehealth platforms now widely prescribe SSRIs including Fluvoxamine. This can be a faster way to get a new prescription or discuss a medication switch. Learn more: How to Find a Doctor Who Can Prescribe Fluvoxamine XR
If you want to stay on Fluvoxamine XR, here are the most effective strategies for locating it:
For our complete guide: How to Find Fluvoxamine XR in Stock Near You
The Fluvoxamine XR shortage has been one of the more persistent drug supply challenges in recent years. With only two manufacturers and ongoing production issues, it's unlikely to fully resolve in the near term.
But you're not powerless. Between stock-checking tools, the widely available IR formulation, effective alternative SSRIs, and discount programs to manage costs, there are real steps you can take to keep your treatment on track. The most important thing is to stay in touch with your prescriber and never stop your medication abruptly.
We'll continue updating this page as the situation evolves. Bookmark it and check back for the latest.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.